OptimizeRx (NASDAQ:OPRX) Given Market Outperform Rating at JMP Securities

JMP Securities restated their market outperform rating on shares of OptimizeRx (NASDAQ:OPRX) in a research note issued to investors on Tuesday morning, Benzinga reports. JMP Securities currently has a $15.00 price objective on the stock.

A number of other brokerages have also recently weighed in on OPRX. Stifel Nicolaus reaffirmed a buy rating and set a $13.00 price target on shares of OptimizeRx in a research report on Monday, April 1st. Barclays began coverage on shares of OptimizeRx in a research report on Wednesday, January 3rd. They set an equal weight rating and a $15.00 price target on the stock. Finally, Royal Bank of Canada reaffirmed an outperform rating and set a $17.00 price target on shares of OptimizeRx in a research report on Monday, April 1st. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus target price of $15.86.

OptimizeRx Stock Performance

OPRX opened at $9.32 on Tuesday. The company’s 50 day simple moving average is $13.24 and its 200 day simple moving average is $11.96. OptimizeRx has a 1 year low of $6.92 and a 1 year high of $16.65. The stock has a market capitalization of $169.44 million, a PE ratio of -9.23 and a beta of 0.98.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. UBS Group AG boosted its stake in shares of OptimizeRx by 290.0% in the third quarter. UBS Group AG now owns 1,997 shares of the company’s stock valued at $29,000 after purchasing an additional 1,485 shares during the period. Nisa Investment Advisors LLC boosted its stake in shares of OptimizeRx by 215.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,142 shares of the company’s stock valued at $31,000 after purchasing an additional 1,462 shares during the period. Captrust Financial Advisors boosted its stake in shares of OptimizeRx by 248.8% in the second quarter. Captrust Financial Advisors now owns 1,287 shares of the company’s stock valued at $35,000 after purchasing an additional 918 shares during the period. Quantbot Technologies LP purchased a new position in shares of OptimizeRx in the third quarter valued at $49,000. Finally, Point72 Hong Kong Ltd purchased a new position in shares of OptimizeRx in the first quarter valued at $52,000. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.